CRISPR Therapeutics has teamed up with General Hospital of Massachusetts to further-widen CRISPR's near-ubiquitous applications. Within this two-year collaboration, CRISPR/Cal9 will also be used in T cell cancer therapies.
Men with early-stage prostate cancer who receive androgen deprivation therapy are at significantly higher risk for heart failure, according to a study published in the British Journal of Cancer. After following a cohort of 7,637 men diagnosed with ...
No comments:
Post a Comment